The University of British Columbia

British Columbia Cancer Agency Branch

University of Alberta

Provincial Health Services Authority

Other

Essa Pharma, Inc.

Cava Healthcare Inc.

Neurodyn, Inc.

Cornell Research Foundation Inc.

Columbia University

Raymond John Andersen

Marianne Dorothy Sadar

Nasrin R Mawji

Carmen Adriana Banuelos

David Williams

Kunzhong Jian

Michel Roberge

Jun Wang

Theresa M Allen

Edward Piers

John Coleman

Javier Garcia Fernandez

Dilip De Silva

Fangming Kong

Debra Wallace

Han-Jie Zhou

Peter Virsik

Wilfred A Jefferies

Reinhard Gabathuler

Lilian Nohara

Mike Leblanc

Stephen G Withers

David L Burgoyne

Gerald Krystal

Christopher J Ong

Michael T Kelly

Gary D Brayer

Jaswinder Bains

Luping Yan

Yu-Chi Yang

E Dilip De Silva

Daniel Andrew Golec

Alice Mui

Andrew Tarling

David E Williams

Jon C Clardy

Robert Britton

Lu Yang

Jasbinder Sanghera

Leslie Karen Williams

Christopher Ariel Shaw

Julie S Racok

Linda S Brinen

Christohper A Shaw

Christina Rose Tysoe

Katherine Woods

Alban Pereira

Xin-Hui Huang

Grant Mauk

Eduardo Vottero

Aruna Balgi

James Nieman

Lu-Ping Yan

Yusuke Imamura

Robert A Britton

Jian Kunzhong

Michael Roberge

Bruno Cinel

Teresa Allen

Amy (Hsing Chen) Tien

Jeff Gerard

Robert Keyzers

Xiaoxia Wang

Todd A Barsby

Labros George Meimetis

Roberto Gs Berlinck

Matthew Bruce Nodwell

Daniel Leung

Andrew C Tarling

Gary Brayer

Marianne D Sadar

Nasrin R Mawjl

Kunzhong Jlan

Hsing Chen Tien

The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.

Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Curcuphenol compounds for increasing MHC-I expression

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, R, R, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Bisphenol derivatives and their use as androgen receptor activity modulators

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, L, L, L, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Bisphenol ether derivatives and methods for using the same

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

Androgen receptor modulators and methods for their use

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, R, R, X, n, n, and nare as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Heterocyclic compounds for cancer imaging and treatment and methods for their use

Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, R, R, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, R, R, X, n, n, and nare as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided. 

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.

Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof

Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, L, L, L, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided. 

Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, Yand Yare as defined herein, and wherein at least one of Ror Ris a straight-chain C-Chaloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.

This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided. 

Diglycidic ether derivative therapeutics and methods for their use

Growing community of inventors

Vancouver, Canada

Raymond John Andersen